Abbott
Company profile
Primary focus
Healthcare technologies, including diagnostics, medical devices, nutrition, and pharmaceuticals.
Why it’s included
The profile lists the 'i-STAT TBI' as a point-of-care test for mild traumatic brain injury, supported by multiple FDA 510(k) clearances and patents for blood-based TBI diagnostics using GFAP and UCH-L1, directly evidencing clinical readiness and topic-specific product development.
Relevant capabilities
- Biomarker assay development and clinical/analytical validation
- Point-of-care and laboratory diagnostic test development (molecular, antigen, serology)
- Clinical laboratory automation and informatics integration
- Regulatory submissions and interactions with major health authorities
- Clinical trial design, execution and diversity initiatives
Commercial sectorPoint-of-Care TBI Blood Test Developers
Technology classesPoint-of-care immunoassay for TBI biomarkers, Automated clinical analyzer immunoassay for brain biomarkers, GFAP and UCH-L1 combination biomarker methods for TBI, Chemiluminescent enzyme immunoassay (CLEIA)
Relevant commercial products
- i-STAT TBI
- Alinity i TBI
- i-STAT TBI blood test
- i-STAT
- i-STAT 1
Relevant patents
5 families, 5 publications- Methods for aiding in diagnosing and evaluating a traumatic brain injury in a human subject using a combination of GFAP and UCH-L1 US-11016105-B2
- Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury in a human subject using early biomarkers US-12099069-B2
- Methods for aiding in diagnosing and evaluating a traumatic brain injury in a human subject using a combination of GFAP and UCH-L1 US-12105100-B2
- Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury using early biomarkers on at least two samples f... US-12085567-B2
- Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker... US-11016092-B2